Virus sample nucleic acid enrichment detection method

By using strongly positively charged amino-surfaced magnetic polystyrene beads for nucleic acid enrichment, the sensitivity and quantification issues in the detection of low-concentration virus samples were solved, achieving efficient nucleic acid separation and purification, and improving the accuracy and sensitivity of detection.

CN118979096APending Publication Date: 2024-11-19SHANGHAI BIOGERM MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411185148.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing technologies lack sufficient sensitivity when detecting extremely low concentrations of viral samples and are difficult to achieve absolute quantification. Nucleic acid separation and measurement are challenging, especially in biologically specific experiments where interference is severe.

Method used

Nucleic acid enrichment is achieved using strongly positively charged amino-surfaced magnetic polystyrene beads. Through incubation, magnetic adsorption, and elution steps, combined with nucleic acid elution buffer, efficient separation and purification of nucleic acids are realized.

Benefits of technology

It improves the recovery rate and detection sensitivity of nucleic acids, enabling accurate quantification in low-concentration virus samples, especially reducing the detection limit of influenza A virus from 1×10³ copies/mL to 1×10 copies/mL.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005013295880000131
    Figure BDA0005013295880000131
  • Figure BDA0005013295880000132
    Figure BDA0005013295880000132
  • Figure BDA0005013295880000141
    Figure BDA0005013295880000141
Patent Text Reader

Abstract

The invention relates to a virus sample nucleic acid enrichment detection method, and particularly provides a nucleic acid enrichment method, a pathogen enrichment method, a nucleic acid detection method and a corresponding kit. The method can effectively distinguish and quantify nucleic acid of a sample (such as an influenza A virus sample) with extremely low concentration in the sample to obtain a high-concentration nucleic acid concentrated solution, so that the sensitivity, the specificity and the accuracy of subsequent detection are improved; powerful technical support is provided for early diagnosis of diseases, epidemic disease monitoring and virus load evaluation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of molecular biology detection, and in particular to a method for detecting nucleic acid enrichment of virus samples. Background Art

[0002] Influenza A virus is a respiratory infectious pathogen that causes a global epidemic. Its rapid and accurate detection is crucial for disease control. Although traditional PCR technology has high sensitivity, it is susceptible to contamination when detecting extremely low concentration samples and it is difficult to achieve absolute quantification. In contrast, digital PCR technology significantly improves the accuracy and sensitivity of detection by dividing the sample into thousands of micro-reaction units, each unit undergoing an independent PCR amplification reaction, and directly counting positive and negative droplets to determine the absolute copy number of the target nucleic acid.

[0003] With the continuous development of modern biological technology, the research results of biological sciences have been widely used. As the carriers of genetic information of organisms, nucleic acids (including DNA and RNA) and their analysis are of great significance in applications such as life analytical chemistry, clinical medical diagnosis, disease prevention, and forensic testing related to the post-genomic era. The purity of nucleic acids is the premise and basis for ensuring the smooth progress of these analyses. In practical applications, nucleic acids are often extracted from living organisms or tissue samples. The presence of multiple body components such as proteins, lipids, and carbohydrates will seriously interfere with the analysis of nucleic acids. Therefore, obtaining nucleic acids of higher purity from complex samples is a prerequisite for subsequent analytical operations.

[0004] Virus detection usually targets nucleic acids, but the existing problem is that nucleic acids are usually present in samples. On the one hand, they are present in very small concentrations, and on the other hand, they are present in many other solid and dissolved substances, such as substances after cell lysis. This makes it difficult to separate or measure nucleic acids, especially in biospecific tests for detecting specific nucleic acids or detecting specific properties of nucleic acids. Such biospecific tests play an important role in the research and development of diagnostics and bioanalysis.

[0005] Therefore, there is an urgent need in the art for a nucleic acid enrichment method with simple operation, high separation efficiency and high recovery rate. Summary of the invention

[0006] The purpose of the present invention is to provide a nucleic acid enrichment method with simple operation, high separation efficiency and high recovery rate.

[0007] The first aspect of the present invention provides a method for enriching nucleic acids, the method comprising the steps of:

[0008] (x1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces;

[0009] (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant;

[0010] (x3) adding the eluent, performing a second magnetic adsorption, and collecting the supernatant, which is the enriched sample; and

[0011] (x4) extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid.

[0012] In another preferred embodiment, the volume ratio of the sample to be enriched to the magnetic polystyrene beads with strongly positively charged amino groups on the surface in the nucleic acid enrichment solution is 500:1 to 500:10.

[0013] In another preferred embodiment, the volume ratio of the sample to be enriched to the strongly positively charged amino-surface magnetic polystyrene beads in the nucleic acid enrichment solution is 400:1 to 400:10, preferably 400:1 or 400:3 or 400:5 (80:1) or 400:7 or 400:10 (40:1), and most preferably 400:5 (80:1).

[0014] In another preferred embodiment, in the step (x4), a nucleic acid eluent is used for nucleic acid extraction, and the volume of the nucleic acid eluent is 10 to 100 μL.

[0015] In another preferred embodiment, the volume of the nucleic acid elution solution is 20 to 80 μL, more preferably 40 to 60 μL, and most preferably 50 μL.

[0016] In another preferred embodiment, the volume ratio of the enriched sample to the nucleic acid eluent is 1:1 to 100:1, preferably 4:1 to 10:1, more preferably 6:1 to 8:1, and most preferably 8:1.

[0017] In another preferred example, the sample to be enriched contains nucleic acid.

[0018] In another preferred example, the sample to be enriched is a virus sample.

[0019] In another preferred embodiment, the virus sample is an influenza A virus sample.

[0020] In another preferred embodiment, the virus concentration in the sample to be enriched is ≥10 copies / mL, preferably ≥100 copies / mL, more preferably ≥1000 copies / mL, and most preferably ≥10000 copies / mL.

[0021] In another preferred embodiment, the sample to be enriched is placed in a sample preservation solution, and the sample preservation solution contains a component selected from the following group: NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof.

[0022] In another preferred embodiment, the nucleic acid enrichment solution further comprises a component selected from the following group: a buffer, a stabilizer, a surfactant, a preservative, or a combination thereof.

[0023] In another preferred embodiment, the particle size of the positively charged amino surface magnetic polystyrene beads is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0024] In another preferred embodiment, the positively charged amino surface magnetic polystyrene beads are placed in pure water or neutral buffer.

[0025] In another preferred embodiment, the content of magnetic polystyrene beads with positively charged amino groups on their surfaces in the nucleic acid enrichment solution is 1-5% (w / v), preferably 2-4%.

[0026] In another preferred embodiment, the material of the positively charged amino surface magnetic polystyrene beads is selected from the following group: ferroferric oxide, silicon dioxide, or a combination thereof.

[0027] In another preferred embodiment, the step (x1) further comprises the step of premixing the sample to be enriched with the buffer solution and then adding the nucleic acid enrichment solution.

[0028] In another preferred embodiment, the buffer is buffer C and / or buffer D.

[0029] In another preferred embodiment, the buffer C consists of the following components: Triton X-100, Tween 20 and ethylphenyl polyethylene glycol.

[0030] In another preferred embodiment, the buffer D consists of the following components: dithiothreitol, tris(2-carboxyethyl)phosphine and β-mercaptoethanol.

[0031] In another preferred embodiment, the volume ratio of buffer C to buffer D is 1-30:1, preferably 5-20:1, more preferably 8-15:1, and most preferably 10:1.

[0032] In another preferred embodiment, the incubation time in step (x1) is 3-20 minutes, preferably 5-10 minutes, and more preferably 6 minutes.

[0033] In another preferred embodiment, the incubation temperature in step (x1) is 20-40°C, preferably 25-37°C.

[0034] In another preferred embodiment, the incubation temperature in step (x1) is room temperature.

[0035] In another preferred embodiment, the mixing step in step (x1) is as follows: invert and mix until the strongly positively charged amino surface magnetic polystyrene beads are evenly distributed in the mixed solution, invert once every 2 minutes, and invert slowly to prevent the generation of too many bubbles.

[0036] In another preferred embodiment, in step (x1), the strongly positively charged amino surface magnetic polystyrene beads are uniformly distributed in the first mixed solution.

[0037] In another preferred embodiment, the time of the first magnetic attraction and the second magnetic attraction is independently 1 to 10 minutes, preferably 3 to 8 minutes, and more preferably 4 to 6 minutes.

[0038] In another preferred embodiment, the eluent is selected from the following group: sodium acetate / acetic acid buffer, sodium citrate / citric acid buffer, citric acid / sodium hydroxide / hydrochloric acid buffer, or a combination thereof.

[0039] In another preferred embodiment, the volume of the eluent is 50-1000 μL, preferably 100-800 μL, more preferably 200-500 μL, and most preferably 400 μL.

[0040] In another preferred embodiment, the volume of the enriched sample is 100-500 μL, preferably 200-400 μL, and more preferably 300-400 μL.

[0041] In another preferred embodiment, in step (x4), an automated nucleic acid extraction system is used to extract nucleic acid.

[0042] In another preferred embodiment, column chromatography is used to purify nucleic acid in step (x4).

[0043] In another preferred embodiment, the nucleic acid recovery rate of the method is ≥75%, preferably ≥80%, preferably ≥90%, more preferably ≥92%, and most preferably ≥95%.

[0044] In another preferred embodiment, the method further comprises the step of identifying and / or detecting the enriched nucleic acid.

[0045] In a second aspect, the present invention provides a method for enriching pathogens, the method comprising the steps of:

[0046] (y1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino surfaces;

[0047] (y2) performing a first magnetic attraction on the first mixed solution and removing the supernatant; and

[0048] (y3) After adding the elution solution, magnetic adsorption is performed for the second time, and the supernatant is collected to obtain enriched pathogens.

[0049] In another preferred embodiment, the sample to be enriched is a clinical sample.

[0050] In another preferred embodiment, the sample to be enriched is a blood sample or a urine sample.

[0051] In another preferred embodiment, the volume ratio of the sample to be enriched to the strongly positively charged amino-surface magnetic polystyrene beads in the nucleic acid enrichment solution is 500:1 to 500:10, preferably 400:1 to 400:10, more preferably 400:1 or 400:3 or 400:5 (80:1) or 400:7 or 400:10 (40:1), and most preferably 400:5 (80:1).

[0052] In another preferred embodiment, the sample to be enriched is a throat swab sample, a nasal swab sample or a respiratory secretion sample, and the pathogen is influenza A virus.

[0053] In another preferred embodiment, the virus concentration in the sample to be enriched is ≥10 copies / mL, preferably ≥100 copies / mL, more preferably ≥1000 copies / mL, and most preferably ≥10000 copies / mL.

[0054] In another preferred embodiment, the sample to be enriched is placed in a sample preservation solution, and the sample preservation solution contains a component selected from the following group: NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof.

[0055] In another preferred embodiment, the particle size of the positively charged amino surface magnetic polystyrene beads is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0056] In another preferred embodiment, the positively charged amino surface magnetic polystyrene beads are placed in pure water or neutral buffer.

[0057] In another preferred embodiment, the content of magnetic polystyrene beads with positively charged amino groups on their surfaces in the nucleic acid enrichment solution is 1-5% (w / v), preferably 2-4%.

[0058] In another preferred embodiment, the material of the positively charged amino surface magnetic polystyrene beads is selected from the following group: ferroferric oxide, silicon dioxide, or a combination thereof.

[0059] In another preferred embodiment, the time of the first magnetic attraction and the second magnetic attraction is independently 1 to 10 minutes, preferably 3 to 8 minutes, and more preferably 4 to 6 minutes.

[0060] In another preferred embodiment, the eluent is selected from the following group: sodium acetate / acetic acid buffer, sodium citrate / citric acid buffer, citric acid / sodium hydroxide / hydrochloric acid buffer, or a combination thereof.

[0061] In another preferred embodiment, the volume of the eluent is 50-1000 μL, preferably 100-800 μL, more preferably 200-500 μL, and most preferably 400 μL.

[0062] In another preferred embodiment, the recovery rate of the method is ≥75%, preferably ≥80%, preferably ≥90%, more preferably ≥92%, and most preferably ≥95%.

[0063] In a third aspect, the present invention provides a kit, comprising:

[0064] (a) a first container, a nucleic acid enriched solution located in the first container, wherein the nucleic acid enriched solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces; and

[0065] (b) a second container, a sample preserving solution located in the second container, wherein the sample preserving solution comprises a component selected from the group consisting of NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof.

[0066] In another preferred embodiment, the particle size of the positively charged amino surface magnetic polystyrene beads is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0067] In another preferred embodiment, the positively charged amino surface magnetic polystyrene beads are placed in pure water or neutral buffer.

[0068] In another preferred embodiment, the content of magnetic polystyrene beads with positively charged amino groups on their surfaces in the nucleic acid enrichment solution is 1-5% (w / v), preferably 2-4%.

[0069] In another preferred embodiment, the material of the positively charged amino surface magnetic polystyrene beads is selected from the following group: ferroferric oxide, silicon dioxide, or a combination thereof.

[0070] In another preferred embodiment, the kit is stored at 0-10°C, preferably 0-5°C.

[0071] In another preferred embodiment, the sample preservation solution comprises the following components:

[0072] 5 to 10 parts by weight of NaCl, 0.01 to 1 parts by weight of KCl, 1 to 5 parts by weight of Na2HPO4, 0.01 to 1 parts by weight of KH2PO4, 0.1 to 10 mg / mL of phenol red, and Proclin-300 containing 1 to 10% CMIT / MIT;

[0073] Preferably, 6 to 9 parts by weight of NaCl, 0.05 to 0.8 parts by weight of KCl, 1 to 4 parts by weight of Na2HPO4, 0.05 to 0.8 parts by weight of KH2PO4, 0.1 to 5 mg / mL of phenol red, and Proclin-300 containing 1 to 5% CMIT / MIT;

[0074] More preferably, 7-9 parts by weight of NaCl, 0.1-0.5 parts by weight of KCl, 2-4 parts by weight of Na2HPO4, 0.1-0.5 parts by weight of KH2PO4, 0.1-1 mg / mL of phenol red, and Proclin-300 containing 2-4% CMIT / MIT.

[0075] In another preferred embodiment, the formula of the sample preservation solution (pH 6.0, 1L) is: 7g NaCl, 0.1g KCl, 2gNa2HPO4 12H2O, 0.1g KH2PO4, 15mL phenol red (0.5mg / mL), 0.5mL Proclin-300 (CMIT / MIT, 3%), and add water to a total volume of 1L.

[0076] In another preferred embodiment, the formula of the sample preservation solution (pH 7.0, 1L) is: 8g NaCl, 0.2g KCl, 3g Na2HPO4 12H2O, 0.25g KH2PO4, 15mL phenol red (0.5mg / mL), 1mL Proclin-300 (CMIT / MIT, 3%), and add water to a total volume of 1L.

[0077] In another preferred embodiment, the formula of the sample preservation solution (pH 8.0, 1L) is: 8.5g NaCl, 0.3g KCl, 3.5g Na2HPO4 12H2O, 0.3g KH2PO4, 15mL phenol red (0.5mg / mL), 2mL Proclin-300 (CMIT / MIT, 3%), and add water to a total volume of 1L.

[0078] In another preferred embodiment, the pH of the sample preservation solution is 5-9, preferably 5.5-8.5, more preferably 6-8, and most preferably 7.

[0079] In another preferred embodiment, the sample preservation solution can keep the sample unchanged for more than 10 months, preferably 12 months, and more preferably 13 months.

[0080] In another preferred embodiment, the kit further comprises a nucleic acid elution solution.

[0081] In another preferred embodiment, the sample preservation solution is used to preserve pathogen samples.

[0082] In another preferred embodiment, the sample includes viruses.

[0083] In another preferred embodiment, the kit is used to preserve samples.

[0084] In another preferred embodiment, the kit is used to enrich the nucleic acid of the sample to be tested.

[0085] In another preferred embodiment, the kit further comprises primers and probes for detecting pathogens.

[0086] In another preferred example, the kit further comprises a PCR reaction solution.

[0087] In another preferred embodiment, the kit is used to detect pathogens.

[0088] In another preferred example, the kit includes an upstream primer having a nucleotide sequence as shown in SEQ ID NO:1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:2, and a probe having a nucleotide sequence as shown in SEQ ID NO:3.

[0089] The fourth method of the present invention provides a method for detecting nucleic acid, comprising the steps of:

[0090] (x1) adding a nucleic acid enrichment solution to the sample to be tested, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces;

[0091] (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant;

[0092] (x3) After adding the eluent, magnetic adsorption is performed for the second time, and the supernatant is collected, which is the enriched sample;

[0093] (x4) extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid; and

[0094] (x5) Using the enriched nucleic acid as a template, a nucleic acid amplification reaction and detection are performed to obtain nucleic acid detection results.

[0095] In another preferred embodiment, the method is used to detect pathogens.

[0096] In another preferred embodiment, the method is a method for non-disease diagnosis purposes.

[0097] In another preferred embodiment, the pathogen includes a virus.

[0098] In another preferred example, the sample to be tested contains nucleic acid.

[0099] In another preferred embodiment, the specificity of the method is ≥99%.

[0100] In another preferred embodiment, the sensitivity of the method is ≥10 copies / mL.

[0101] In another preferred embodiment, the detection in step (x5) is fluorescence signal detection.

[0102] In another preferred embodiment, the nucleic acid amplification reaction is selected from the following group: PCR, qPCR, ddPCR, RT-PCR, RT-qPCR, ARMS-PCR, and LAMP.

[0103] In another preferred embodiment, the detection limit of the method is ≤1 copy / μL, preferably ≤0.1 copy / μL, and more preferably ≤0.01 copy / μL.

[0104] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0105] Figure 1 The ddPCR results using the sample preservation solution of the present invention are shown. DETAILED DESCRIPTION

[0106] After extensive and in-depth research, a large number of experiments and screening, the inventors have discovered for the first time a pathogen and a method for enriching nucleic acids thereof. Through screening and optimization of sample preservation solution, enrichment magnetic beads, sample / magnetic bead ratio, sample / elution ratio, specific primer probes and other aspects, the method of the present invention can not only ensure that the collected samples can remain stable within 13 months, but also obtain a high-concentration nucleic acid concentrate, which is conducive to improving the sensitivity, specificity and accuracy of subsequent detection. The nucleic acid detection method of the present invention can greatly improve the detection limit of samples to be tested, such as viruses (especially influenza A viruses), from 1×10 3 The number of copies / mL was increased to 1×10 copies / mL, solving the technical problem that low-load samples cannot be accurately quantified. On this basis, the present invention was completed.

[0107] the term

[0108] In order to more easily understand the present invention, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions, because such methods and conditions can be changed. It should also be understood that the terms used herein are intended only to describe specific embodiments, and are not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.

[0109] As used herein, the term “comprise” or variations thereof such as “include” or “comprising”, etc., are understood to include the stated elements or components but do not exclude other elements or components.

[0110] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0111] As used herein, unless otherwise indicated, any concentration range, percentage range, ratio range or integer range should be understood to include any integer value within the range and fractional values ​​thereof (e.g., one tenth and one hundredth of an integer) where appropriate.

[0112] As used herein, the term "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items.

[0113] Magnetic beads of the present invention

[0114] In this document, the terms "magnetic beads of the present invention" and "strongly positively charged amino surface magnetic polystyrene magnetic beads" are used interchangeably. The magnetic beads used in the specific embodiment of the present invention are Dynabeads TM Magnetic beads (ThermoFisher, Cat. No. 10700D).

[0115] In a preferred embodiment, the particle size of the magnetic beads of the present invention is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0116] In a preferred embodiment, the magnetic beads of the present invention are placed in pure water or a neutral buffer.

[0117] In a preferred embodiment, the material of the magnetic beads of the present invention is selected from the following group: ferroferric oxide, silicon dioxide, or a combination thereof.

[0118] In a preferred embodiment, the magnetic beads of the present invention are stored at 0-10°C, preferably 2-8°C.

[0119] Nucleic acid enrichment method of the present invention

[0120] The nucleic acid enrichment method of the present invention comprises the steps of:

[0121] (x1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces;

[0122] (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant;

[0123] (x3) adding the eluent, performing a second magnetic adsorption, and collecting the supernatant, which is the enriched sample; and

[0124] (x4) extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid.

[0125] In a preferred embodiment, the volume ratio of the sample to be enriched to the magnetic polystyrene beads with strong positively charged amino groups on the surface in the nucleic acid enrichment solution is 500:1 to 500:10, preferably 400:1 to 400:10, more preferably 400:1 or 400:3 or 400:5 (80:1) or 400:7 or 400:10 (40:1), and most preferably 400:5 (80:1). When the volume ratio of the sample to be enriched to the magnetic polystyrene beads with strong positively charged amino groups on the surface in the nucleic acid enrichment solution is 80:1, the enrichment effect of the method is the best, and the recovery rate of nucleic acid is 95%.

[0126] In a preferred embodiment, in step (x4), a nucleic acid eluent is used for nucleic acid extraction, and the volume of the nucleic acid eluent is 10 to 100 μL, preferably 20 to 80 μL, more preferably 40 to 60 μL, and most preferably 50 μL.

[0127] In a preferred embodiment, the volume ratio of the enriched sample to the nucleic acid eluent is 1:1 to 100:1, preferably 4:1 to 10:1, more preferably 6:1 to 8:1, and most preferably 8:1. When the volume ratio of the enriched sample to the nucleic acid eluent is 8:1, the method has the best enrichment effect, and the nucleic acid recovery rate is 95%.

[0128] In a preferred embodiment, the nucleic acid enrichment solution further comprises a component selected from the group consisting of a buffer, a stabilizer, a surfactant, a preservative, or a combination thereof.

[0129] In a preferred embodiment, the sample to be enriched is placed in a sample preservation solution, and the sample preservation solution comprises a component selected from the group consisting of NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof. The sample preservation solution of the present invention is used to preserve the sample, and the sample can be kept stable for 13 months.

[0130] In a preferred embodiment, the step (x1) further comprises the step of premixing the sample to be enriched with buffer C and / or buffer D before adding the nucleic acid enrichment solution. The buffer C is selected from the group consisting of Triton X-100, Tween 20, ethylphenyl polyethylene glycol, or a combination thereof. The buffer D is selected from the group consisting of dithiothreitol, tris(2-carboxyethyl)phosphine, β-mercaptoethanol, or a combination thereof. The volume ratio of the buffer C to the buffer D is 1 to 30:1, preferably 5 to 20:1, more preferably 8 to 15:1, and most preferably 10:1.

[0131] In a preferred embodiment, the eluent is selected from the following group: sodium acetate / acetic acid buffer, sodium citrate / citric acid buffer, or citric acid / sodium hydroxide / hydrochloric acid buffer.

[0132] Pathogen enrichment method of the present invention

[0133] The pathogen enrichment method of the present invention comprises the steps of:

[0134] (y1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino surfaces;

[0135] (y2) performing a first magnetic attraction on the first mixed solution and removing the supernatant; and

[0136] (y3) After adding the elution solution, magnetic adsorption is performed for the second time, and the supernatant is collected to obtain enriched pathogens.

[0137] In a preferred embodiment, the sample to be enriched is a clinical sample.

[0138] In a preferred embodiment, the sample to be enriched is a blood sample or a urine sample.

[0139] In a preferred embodiment, the volume ratio of the sample to be enriched to the magnetic polystyrene beads with strong positively charged amino groups on the surface in the nucleic acid enrichment solution is 500:1 to 500:10, preferably 400:1 to 400:10, more preferably 400:1 or 400:3 or 400:5 (80:1) or 400:7 or 400:10 (40:1), and most preferably 400:5 (80:1). When the volume ratio of the sample to be enriched to the magnetic polystyrene beads with strong positively charged amino groups on the surface in the nucleic acid enrichment solution is 80:1, the enrichment effect of the method is the best, and the recovery rate of nucleic acid is 95%.

[0140] In a preferred embodiment, the sample to be enriched is a throat swab sample, a nasal swab sample or a respiratory secretion sample.

[0141] In a preferred embodiment, the virus concentration in the sample to be enriched is ≥10 copies / mL, preferably ≥100 copies / mL, more preferably ≥1000 copies / mL, and most preferably ≥10000 copies / mL.

[0142] In a preferred embodiment, the sample to be enriched is placed in a sample preservation solution, and the sample preservation solution contains a component selected from the following group: NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof.

[0143] In a preferred embodiment, the particle size of the positively charged amino surface magnetic polystyrene beads is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0144] In a preferred embodiment, the positively charged amino surface magnetic polystyrene beads are placed in pure water or a neutral buffer.

[0145] In a preferred embodiment, the content of positively charged amino-surface magnetic polystyrene beads in the nucleic acid enrichment solution is 1-5% (w / v), preferably 2-4%.

[0146] In a preferred embodiment, the material of the positively charged amino surface magnetic polystyrene beads is selected from the following group: ferrosoferric oxide, silicon dioxide, or a combination thereof.

[0147] In a preferred embodiment, the time for the first magnetic attraction and the second magnetic attraction is independently 1 to 10 minutes, preferably 3 to 8 minutes, and more preferably 4 to 6 minutes.

[0148] In a preferred embodiment, the eluent is selected from the group consisting of sodium acetate / acetic acid buffer, sodium citrate / citric acid buffer, citric acid / sodium hydroxide / hydrochloric acid buffer, or a combination thereof.

[0149] In a preferred embodiment, the volume of the eluent is 50-1000 μL, preferably 100-800 μL, more preferably 200-500 μL, and most preferably 400 μL.

[0150] In a preferred embodiment, the recovery rate of the method is ≥75%, preferably ≥80%, preferably ≥90%, more preferably ≥92%, and most preferably ≥95%.

[0151] Kit of the present invention

[0152] The kit of the present invention comprises:

[0153] (a) a first container, a nucleic acid enriched solution located in the first container, wherein the nucleic acid enriched solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces; and

[0154] (b) a second container, a sample preserving solution located in the second container, wherein the sample preserving solution comprises a component selected from the group consisting of NaCl, KCl, Na2HPO4 12H2O, KH2PO4, phenol red, Proclin-300, or a combination thereof.

[0155] In a preferred embodiment, the particle size of the positively charged amino surface magnetic polystyrene beads is 0.4-0.8 μm, preferably 0.5-0.7 μm.

[0156] In a preferred embodiment, the positively charged amino surface magnetic polystyrene beads are placed in pure water or a neutral buffer.

[0157] In a preferred embodiment, the content of positively charged amino-surface magnetic polystyrene beads in the nucleic acid enrichment solution is 1-5% (w / v), preferably 2-4%.

[0158] In a preferred embodiment, the material of the positively charged amino surface magnetic polystyrene beads is selected from the following group: ferrosoferric oxide, silicon dioxide, or a combination thereof.

[0159] In a preferred embodiment, the kit is stored at 0-10°C, preferably 0-5°C.

[0160] In a preferred embodiment, the sample preservation solution comprises the following components:

[0161] 5 to 10 parts by weight of NaCl, 0.01 to 1 parts by weight of KCl, 1 to 5 parts by weight of Na2HPO4, 0.01 to 1 parts by weight of KH2PO4, 0.1 to 10 mg / mL of phenol red, and Proclin-300 containing 1 to 10% CMIT / MIT;

[0162] Preferably, 6 to 9 parts by weight of NaCl, 0.05 to 0.8 parts by weight of KCl, 1 to 4 parts by weight of Na2HPO4, 0.05 to 0.8 parts by weight of KH2PO4, 0.1 to 5 mg / mL of phenol red, and Proclin-300 containing 1 to 5% CMIT / MIT;

[0163] More preferably, 7-9 parts by weight of NaCl, 0.1-0.5 parts by weight of KCl, 2-4 parts by weight of Na2HPO4, 0.1-0.5 parts by weight of KH2PO4, 0.1-1 mg / mL of phenol red, and Proclin-300 containing 2-4% CMIT / MIT.

[0164] In a preferred embodiment, the formula of the sample preservation solution (pH 8.0, 1L) is: 8.5g NaCl, 0.3g KCl, 3.5g Na2HPO4 12H2O, 0.3g KH2PO4, 15mL phenol red (0.5mg / mL), 2mL Proclin-300 (CMIT / MIT, 3%), and water is added to a total volume of 1L.

[0165] In a preferred embodiment, the pH of the sample preservation solution is 5-9, preferably 5.5-8.5, more preferably 6-8, and most preferably 7.

[0166] In a preferred embodiment, the sample preservation solution can keep the sample unchanged for more than 10 months, preferably 12 months, and more preferably 13 months.

[0167] In a preferred embodiment, the kit further comprises a nucleic acid elution solution.

[0168] In a preferred embodiment, the kit is used to preserve a sample.

[0169] In a preferred embodiment, the kit is used to enrich nucleic acids in a sample to be tested.

[0170] In a preferred embodiment, the kit further comprises primers and probes for detecting pathogens.

[0171] In a preferred embodiment, the kit further comprises a PCR reaction solution.

[0172] In a preferred embodiment, the kit is used to detect pathogens.

[0173] In a preferred embodiment, the kit comprises an upstream primer having a nucleotide sequence as shown in SEQ ID NO:1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:2, and a probe having a nucleotide sequence as shown in SEQ ID NO:3.

[0174] Nucleic acid detection method of the present invention

[0175] The nucleic acid detection method of the present invention comprises the steps of:

[0176] (x1) adding a nucleic acid enrichment solution to the sample to be tested, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces;

[0177] (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant;

[0178] (x3) After adding the eluent, magnetic adsorption is performed for the second time, and the supernatant is collected, which is the enriched sample;

[0179] (x4) extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid; and

[0180] (x5) Using the enriched nucleic acid as a template, a nucleic acid amplification reaction and detection are performed to obtain nucleic acid detection results.

[0181] In a preferred embodiment, the method is used to detect pathogens.

[0182] In a preferred embodiment, the method is a method for non-disease diagnosis purposes.

[0183] In a preferred embodiment, the pathogen comprises a virus.

[0184] In a preferred embodiment, the sample to be tested contains nucleic acid.

[0185] In a preferred embodiment, the specificity of the method is ≥ 99%.

[0186] In a preferred embodiment, the sensitivity of the method is ≥10 copies / mL.

[0187] In a preferred embodiment, the detection in step (x5) is fluorescence signal detection.

[0188] In a preferred embodiment, the nucleic acid amplification reaction is selected from the following group: PCR, qPCR, ddPCR, RT-PCR, RT-qPCR, ARMS-PCR, LAMP.

[0189] In a preferred embodiment, the detection limit of the method is ≤1 copy / μL, preferably ≤0.1 copy / μL, and more preferably ≤0.01 copy / μL.

[0190] The main advantages of the present invention include:

[0191] 1. The method of the present invention can be used to obtain a high-concentration nucleic acid concentrate, thereby improving the sensitivity, accuracy and specificity of the detection method.

[0192] 2. The method of the present invention is simple to operate, low in cost and has a wide range of applications.

[0193] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0194] General Methods

[0195] Development of sample preservation solution: To ensure the stability of the samples, a new sample preservation solution was designed that can ensure that the samples remain stable within 13 months.

[0196] Sample preparation: Collect clinical specimens suspected of being infected with influenza A virus (such as throat swabs, nasal swabs or respiratory secretions) and place them in a preservation tube containing sample preservation solution.

[0197] Enrichment magnetic bead screening: Use magnetic beads modified with different groups to enrich pathogens and screen out the magnetic beads with the best enrichment effect.

[0198] Influenza A virus enrichment: The samples prepared in the first step are used to enrich the pathogen using specially modified magnetic beads, which are then used for nucleic acid extraction and purification.

[0199] Nucleic acid extraction and purification: The total RNA was extracted from the treated samples using the automated extraction system of Shanghai Bio-Tech Co., Ltd. and purified by column chromatography or other appropriate methods to remove impurities that may interfere with subsequent reactions.

[0200] Specific primer and probe design: Design specific primers and fluorescently labeled hydrolysis probes targeting the conserved regions of influenza A virus (such as the M gene or HA gene) to ensure high specificity and sensitivity of the detection.

[0201] Microdroplet generation: After the purified nucleic acid template is mixed with the optimized PCR reaction mixture (including specific primers, probes, dNTPs, Taq enzyme, etc.) in the proportion required by the digital PCR platform, the mixture is uniformly divided into thousands of tiny reaction units through oil-water two-phase microfluidics technology or other microdroplet generation methods.

[0202] Digital PCR amplification and detection: Under standardized temperature cycle conditions, the nucleic acid template in each droplet undergoes independent PCR amplification. After the amplification is completed, a special reading system (such as a fluorescence detector) is used to detect the fluorescence signal of each droplet to distinguish between positive (fluorescence signal exceeds the threshold) and negative (no fluorescence or fluorescence below the threshold) droplets.

[0203] Data analysis: The absolute copy number of influenza A virus nucleic acid in the sample was calculated based on the number of positive droplets and the total number of droplets, combined with the known droplet volume and the initial distribution of nucleic acid in the reaction system.

[0204] Example 1

[0205] In this example, samples collected from patients infected with influenza A were placed in sample preservation solutions of different formulations shown in Table 1 and monitored in real time for 13 months. The monitoring results are shown in Table 2.

[0206] Table 1

[0207]

[0208] Table 2

[0209]

[0210]

[0211] As shown in Table 2, the average ct value of the samples in formula 2 is the smallest and the storage is the most stable.

[0212] Example 2

[0213] In this example, influenza A samples (placed in sample preservation solution) were enriched with different types of magnetic beads. The enrichment effects of different types of magnetic beads are evaluated in Table 3.

[0214] Table 3

[0215]

[0216]

[0217] The results showed that under the same conditions, magnetic polystyrene beads modified with strong positive charge (amino group) had the best enrichment effect.

[0218] Example 3

[0219] The influenza sample of influenza A was enriched for virus. The enrichment process was as follows: 200 μL buffer C and 20 μL buffer D were added to 4 mL of the sample to be enriched (placed in the sample preservation solution), and the mixture was mixed by inversion; 30 μL-100 μL of magnetic beads were added to the sample to be enriched, incubated at room temperature for 6 minutes, and mixed by inversion until the magnetic beads were evenly distributed in the liquid. The sample was inverted every 2 minutes, and it was necessary to invert slowly to prevent the generation of many bubbles; the sample centrifuge tube was placed on a magnetic rack, and the magnet was absorbed for 5 minutes. After the supernatant was clarified, the supernatant was aspirated from the centrifuge tube with a pipette and discarded; 400 μL of elution solution was added to a 1.5 mL centrifuge tube, and then placed on a magnetic rack, and the magnet was absorbed for 5 minutes. The collected supernatant was the concentrated solution of the water sample, with a volume of about 400 μL, which could be used as a sample for nucleic acid extraction. The evaluation of the enrichment effect of different combinations is shown in Table 4.

[0220] Table 4

[0221]

[0222] After testing this kit, it was found that adding 50μl of magnetic beads to 4mL of sample had the best enrichment effect.

[0223] Example 4

[0224] The enriched samples were subjected to nucleic acid extraction and purification, using the nucleic acid extraction process with the nucleic acid extraction and purification reagent registration number of "Shanghai Fengxiebei 20180202", and the operation was performed according to the extraction reagent instructions. The evaluation of the recovery effect of different combinations is shown in Table 5.

[0225] Table 5

[0226]

[0227]

[0228] The results showed that after testing and optimization, the kit was found to have the highest nucleic acid recovery efficiency when the sample loading volume was 400 μL and the elution volume was 50 μL.

[0229] Example 5

[0230] This embodiment includes preparing ddPCR reaction solution, preparing droplets, digital PCR amplification and detection.

[0231] The one-step ddPCR probe method premix includes: 15μl PCR Buffer, 0.4μl upstream and downstream primers, 0.1μl specific probe, and the concentrations of primers and probes are both 100μM. 15μl sample nucleic acid, total volume 30.9μl.

[0232] The process of preparing microdroplets is as follows: according to the marked positions on the droplet generation plate, 30.9 μL of aqueous reaction system and 180 μL of microdroplet generation oil are added to the corresponding solution wells using an 8-channel pipette. Then the base with the droplet generation card fixed is placed in the droplet generator to generate droplets, and the 8-row tube is taken out to complete the droplet preparation;

[0233] The digital PCR amplification process is as follows: 55°C, 15 min, 95°C, 10 min; 94°C, 30 s, 55°C, 1 min, 40 cycles; 12°C, ∞.

[0234] The sensitivity of the detection method using the primers and specific probes shown in Table 6 is as follows:

[0235] Table 6

[0236] name sequence SEQ ID NO: Upstream primer ACCRATCCTGTCACCTCTGA 1 Downstream primer GCATTYTGGACAAAKCGTCTAC 2 Probe GCAGTCCTCGCTCACTGGGCAC 3

[0237] In this experiment, five concentrations (1×10 5 copies / mL, 1×10 4 copies / mL, 1×10 3 copies / mL, 1×10 2 The influenza A virus with a concentration of 1×10 copies / mL and 1×10 copies / mL was enriched according to Example 2, the nucleic acid was extracted according to Example 3, and the detection was performed according to Example 4.

[0238] The experimental results are as follows Figure 1 As shown, the minimum detection limit of the ddPCR detection method established in the present invention is 1×10 copies / mL (0.01 copies / μL).

[0239] Example 6

[0240] This example verifies that the sensitivity of the detection method of the present invention is higher than that of other methodologies. The specific operation is as follows: In this experiment, 5 concentrations (1×10 5 copies / mL, 1×10 4 copies / mL, 1×10 3 copies / mL, 1×10 2 The experimental group was subjected to sample enrichment according to Example 3, nucleic acid extraction according to Example 4, and detection according to Example 5. The control group was subjected to conventional treatment, with the process of nucleic acid extraction according to Example 4 and detection according to Example 5. Table 7 shows the difference in sensitivity between the experimental group and the control group.

[0241] Table 7

[0242] Sample No. Influenza A virus concentration Number of positive droplets in the experimental group Number of positive droplets in the control group 1 <![CDATA[1×10 5 copies / mL]]> 6150 515 2 <![CDATA[1×10 4 copies / mL]]> 390 37 3 <![CDATA[1×10 3 copies / mL]]> 70 5 4 <![CDATA[1×10 2 copies / mL]]> 20 0 5 1×10 copies / mL 6 0

[0243] From the above results, it can be seen that the present invention can ensure that the collected samples can remain stable within 13 months through the development of sample preservation solution, the application of enrichment system, and the application of influenza A specific primer probe, and quantitative detection can be performed at any time within the effective time. Through the application of enrichment system, the detection limit of influenza A virus is greatly improved from 1×10 3 The number of copies / mL was increased to 1×10 copies / mL, solving the technical problem of inability to accurately quantify low-load samples.

[0244] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for enriching nucleic acids, It is characterized in that The method comprises the steps of: (x1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces; (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant; (x3) adding the eluent, performing a second magnetic adsorption, and collecting the supernatant, which is the enriched sample; and (x4) Extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid.

2. The method according to claim 1, It is characterized in that The volume ratio of the sample to be enriched to the magnetic polystyrene beads with strong positive charge amino groups on the surface in the nucleic acid enrichment solution is 500:1 to 500:

10.

3. The method according to claim 1, It is characterized in that In the step (x4), a nucleic acid eluent is used to extract nucleic acid, and the volume of the nucleic acid eluent is 10 to 100 μL.

4. A pathogen enrichment method, It is characterized in that The method comprises the steps of: (y1) adding a nucleic acid enrichment solution to the sample to be enriched, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino surfaces; (y2) performing a first magnetic attraction on the first mixed solution and removing the supernatant; and (y3) After adding the elution solution, magnetic adsorption is performed for the second time, and the supernatant is collected to obtain enriched pathogens.

5. The method according to claim 4, It is characterized in that The sample to be enriched is a throat swab sample, a nasal swab sample or a respiratory secretion sample, and the pathogen is influenza A virus.

6. A kit, It is characterized in that The kit comprises: (a) a first container, a nucleic acid enriched solution located in the first container, wherein the nucleic acid enriched solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces; and (b) a second container, a sample preserving solution in the second container, wherein the sample preserving solution comprises a component selected from the group consisting of: NaCl, KCl, Na 2 HPO 4 12H 2 O.KH 2 PO 4 , phenol red, Proclin-300, or a combination thereof.

7. The kit according to claim 6, It is characterized in that The sample preservation solution comprises the following components: 5 to 10 parts by weight of NaCl, 0.01 to 1 parts by weight of KCl, 1 to 5 parts by weight of Na 2 HPO 4 , 0.01 to 1 parts by weight of KH 2 PO 4 , 0.1-10 mg / mL phenol red and Proclin-300 containing 1-10% CMIT / MIT.

8. The kit according to claim 6, It is characterized in that The kit comprises an upstream primer having a nucleotide sequence as shown in SEQ ID NO:1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:2 and a probe having a nucleotide sequence as shown in SEQ ID NO:

3.

9. A method for nucleic acid detection, It is characterized in that The method comprises the steps of: (x1) adding a nucleic acid enrichment solution to the sample to be tested, incubating and mixing, to obtain a first mixed solution; wherein the nucleic acid enrichment solution comprises magnetic polystyrene beads with strongly positively charged amino groups on their surfaces; (x2) performing a first magnetic attraction on the first mixed solution and removing the supernatant; (x3) After adding the eluent, magnetic adsorption is performed for the second time, and the supernatant is collected, which is the enriched sample; (x4) extracting and / or purifying nucleic acid from the enriched sample to obtain enriched nucleic acid; and (x5) Using the enriched nucleic acid as a template, a nucleic acid amplification reaction and detection are performed to obtain nucleic acid detection results.

10. The method according to claim 9, It is characterized in that The nucleic acid amplification reaction is selected from the following group: PCR, qPCR, ddPCR, RT-PCR, RT-qPCR, ARMS-PCR, LAMP.